
Europe Plant-based Vaccines Market
No. of Pages: 132 | Report Code: TIPRE00026267 | Category: Life Sciences
No. of Pages: 132 | Report Code: TIPRE00026267 | Category: Life Sciences
Market Introduction
The Europe Plant-based vaccines market includes the consolidated markets for Germany, France, the United Kingdom, and Rest of Europe. Europe is the second largest market in the forecast period owing to factors such as rising geriatric population, increasing prevalence of chronic viral diseases, and high demand for the development of new antigen in the region. In addition, growing funding for research & development activities is likely to add more opportunities in coming years, in the region.
Reliable and timely COVID-19 testing is an integral part of the monitoring, prevention, touch recording, and control of infections, and clinical management of COVID-19. The European Center for Disease Prevention and Control (ECDC) has proposed an analytical testing strategy for the EU with concrete guidelines on the level of dissemination of viruses in the population, considering the available public health tools and testing ability. A survey undertaken by the European Commission Health Protection Committee in September 2020 investigated the activities of Member States in the use of rapid antigen tests. Fifteen EU member states responded to the survey, out of them five states are using rapid antigen tests on certain aspects of the response to the COVID-19 pandemic. Nine of the fifteen countries are currently conducting clinical validation trials or pilots to evaluate the clinical/diagnostic efficiency and future use of rapid antigen tests, and 2 member states are not considering the use of rapid antigen tests. According to the report, some countries use the tests as part of their research policy for early detection of infection, contact tracking and/or rapid isolation, and quarantine of identified cases and their contacts. Other countries use rapid antigen tests explicitly to ensure laboratory testing in remote areas where the RT-PCR gold standard is not available or timely enough.
Market Overview and Dynamics
The plant-based vaccines market in Europe is expected to grow from US$ 306.40 million in 2021 to US$ 705.15 million by 2028; it is estimated to grow at a CAGR of 12.6% from 2021 to 2028. influenza is a highly contagious respiratory ailment caused by influenza viruses. Influenza viruses are constantly changing genetically, highly impacting induced immunity and vaccine formulation. According to the World Health Organization (WHO), when infected individual coughs or sneezes, droplets containing viruses (infectious droplets) are disseminated into the air and can travel up to one-meter, infecting people in close proximity who breathe these droplets in. Pregnant women, pediatricians, geriatricians, patients with low immunity who have chronic conditions, and healthcare workers are all at risk for influenza infection. As a result, the Europe need for vaccines has skyrocketed. Such factors are likely to propel the worldwide plant-based vaccines market forward during the forecast period.
Key Market Segments
Europe plant-based vaccines market is segmented into vaccine type, source, application, and country. Based on vaccine type, the Europe plant-based vaccines market is segmented into bacterial vaccines, viral vaccines, parasite vaccines, plant-derived virus-like particles, and others. The bacterial vaccines segment held the largest share of the market in 2021. Based on source, the Europe plant-based vaccines market is segmented into tobacco plant, maize, potato, and others. The tobacco plant segment held the largest share of the market in 2021. Based on application, the Europe plant-based vaccines market is segmented into influenza, zika virus, Ebola virus, poultry disease, COVID-19, and others. The influenza segment held the largest share of the market in 2021. Based on country, the Europe plant-based vaccines market is segmented into France, Germany, Italy, Spain, the UK, and rest of Europe. Germany held the largest market share in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the plant-based vaccines market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are British American Tobacco p.l.c.; Creative Biolabs, Inc.; Leaf Expression Systems Ltd.; LenioBio; Lumen Bioscience, Inc.; and ZYUS Life Sciences Inc.
Reasons to buy report
Europe
Plant-based Vaccines Market
Segmentation
Europe Plant-based Vaccines Market -
By Vaccine Type
Europe Plant-based Vaccines Market - By
Source
Europe Plant-based Vaccines Market - By Application
Europe Plant-based Vaccines Market - By Country
Europe Plant-based Vaccines Market - Company Profiles
Strategic insights for the Europe Plant-based Vaccines provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 306.40 Million |
Market Size by 2028 | US$ 705.15 Million |
Global CAGR (2021 - 2028) | 12.6% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Vaccine Type
|
Regions and Countries Covered | Europe
|
Market leaders and key company profiles |
The geographic scope of the Europe Plant-based Vaccines refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The Europe Plant-based Vaccines Market is valued at US$ 306.40 Million in 2021, it is projected to reach US$ 705.15 Million by 2028.
As per our report Europe Plant-based Vaccines Market, the market size is valued at US$ 306.40 Million in 2021, projecting it to reach US$ 705.15 Million by 2028. This translates to a CAGR of approximately 12.6% during the forecast period.
The Europe Plant-based Vaccines Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Plant-based Vaccines Market report:
The Europe Plant-based Vaccines Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Plant-based Vaccines Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Plant-based Vaccines Market value chain can benefit from the information contained in a comprehensive market report.